Bristol Myers says KRAS drug succeeds in key trial
Bio Pharma Dive
MARCH 29, 2024
Confirmatory results for Krazati, which Bristol Myers acquired via its buyout of Mirati, could help the drug win full approval while Amgen has been set back.
Fri.Mar 29, 2024
305 
Gilead’s Vemlidy expands label to treat paediatric chronic HBV
Pharmaceutical Technology
MARCH 29, 2024
Vemlidy was first approved to treat adults with HBV in 2016. Its label was expanded in 2022 for use in patients 12 years and older.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Pulse 3/29/24: Social Media Users Turn to Twitter for Guidance on Birth Control, Wider Availability of Oral Contraceptives & more
Pharmaceutical Commerce
MARCH 29, 2024
The latest news for pharma industry insiders.
Sun Pharmaceutical Industries gets grant for dermal patch system for collecting physiological samples
Pharmaceutical Technology
MARCH 29, 2024
Discover the innovative dermal patch system by Sun Pharmaceutical Industries Ltd for efficient and minimally invasive physiological sample collection. Patent US11877848B2 revolutionizes sample processing with a unique design.
Bridging Innovation & Patient Care: The Growing Role of AI
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Report claims WuXi shared US client IP with China
pharmaphorum
MARCH 29, 2024
Report claims US intelligence services advised the authors of the BIOSECURE Act that WuXi AppTec shared confidential data on US clients with the Chinese government
Yield10 Bioscience gets grant for genetically engineered oilseed plant expressing plant protein
Pharmaceutical Technology
MARCH 29, 2024
Discover the groundbreaking patent by Yield10 Bioscience Inc for a genetically engineered oilseed plant expressing a plant protein, revolutionizing biotechnology in agriculture.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Crinetics Pharmaceuticals gets grant for patent granted for somatostatin modulators for treating hormone-related conditions
Pharmaceutical Technology
MARCH 29, 2024
Discover how Crinetics Pharmaceuticals Inc's patent for compounds modulating somatostatin activity can suppress hormone secretion in mammals. Explore the detailed framework for hormone modulation and SSTR2 activity regulation.
Disappointment for BMS as Zeposia fails Crohn’s study
pharmaphorum
MARCH 29, 2024
Bristol-Myers Squibb's Zeposia has failed to outperform placebo in its first phase 3 test in Crohn's disease
Gamida Cell gets grant for method of preparing transplantable NK cell fraction for transplantation
Pharmaceutical Technology
MARCH 29, 2024
Expand transplantable NK cell fractions for cancer treatment with Gamida Cell's patented method. Culturing, supplementing, and storing cells ensure improved outcomes for cancer patients.
Bristol Myers Squibb's versatile Zeposia doesn't make the grade in Crohn's disease trial
Fierce Pharma
MARCH 29, 2024
Bristol Myers Squibb’s Zeposia (ozanimod) has attracted attention as a treatment for an unusual duo of diseases—multiple sclerosis (MS) and ulcerative colitis (UC). | Bristol Myers Squibb’s Zeposia has attracted attention as a treatment for an odd pair of unrelated diseases—multiple sclerosis (MS) and ulcerative colitis (UC). But the approval roll for the sphingosine 1-phosphate (S1P) receptor modulator may be over.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Rohto Pharmaceutical gets grant for ophthalmic composition for treating myopia with crocetin and ginkgo leaf
Pharmaceutical Technology
MARCH 29, 2024
Discover Rohto Pharmaceutical's patented ophthalmic composition with crocetin and ginkgo leaf extract, proven to prevent and treat myopia in all ages. Explore the groundbreaking method for treating axial myopia and ocular diseases.
After Amgen's stumble, BMS touts KRAS confirmatory trial win for newly bought Krazati
Fierce Pharma
MARCH 29, 2024
Bristol Myers Squibb looks on track to overtake Amgen as the KRAS leader in lung cancer after following up its rival’s FDA setback with a positive confirmatory trial readout. | Bristol Myers Squibb looks on track to overtake Amgen as the KRAS leader in lung cancer after following up its rival’s FDA setback with a positive confirmatory trial readout.
Angelini gets grant for method for labelling reels using robot and application roller
Pharmaceutical Technology
MARCH 29, 2024
Revolutionize your labeling process with Angelini Spa's patented method using a robot and label printer to efficiently attach printed labels to reels. Patent Publication Number: US11884443B2.
'Unprecedented' demand for Eli Lilly's Zepbound sparks US supply constraints
Fierce Pharma
MARCH 29, 2024
Once again, a medicine in the popular GLP-1 class of diabetes and weight loss therapies is facing supply hurdles. | While the drug is not listed on the FDA's shortage list, some pharmacies are facing supply issues. Amazon Pharmacy, for instance, notes that several dosage strengths are "unavailable.
Chong Kun Dang Pharmaceutical gets grant for injectable composition of testosterone undecanoate for testosterone deficiency treatment
Pharmaceutical Technology
MARCH 29, 2024
Discover the innovative injectable composition of testosterone undecanoate by Chong Kun Dang Pharmaceutical Corporation. Patented for treating testosterone deficiency, this composition offers enhanced stability and ease of use during injection.
The unrecognized threat of PAD
Fierce Pharma
MARCH 29, 2024
This week on “The Top Line,” we explore peripheral arterial disease, a serious health issue that is often overlooked and undermanaged. | This week on “The Top Line,” join Editor-in-Chief of Fierce Life Sciences and Healthcare Ayla Ellison as she sits down with Kumar Madassery, M.D., Director of Peripheral Vascular Intervention & CLI Program at Rush University Medical Center, to explore peripheral arterial disease—a serious health issue that is often overlooked and undermanaged.
CSL gets grant for method of reducing GVHD risk in hct patients with a1at
Pharmaceutical Technology
MARCH 29, 2024
Discover how CSL Ltd's patented method using alpha-1 antitrypsin (A1AT) can reduce the risk of graft versus host disease in hematopoietic cell transplantation patients. Published as US11857610B2, this groundbreaking approach offers hope for improved outcomes.
Teva, following Hikma complaint, alleges Amarin 'locked up' Vascepa ingredient to block generics
Fierce Pharma
MARCH 29, 2024
A little more than a year after Hikma Pharmaceuticals accused Amarin of “deliberately and meticulously” hamstringing supplies of the main ingredient in its only marketed drug, Vascepa, to thwart po | A little more than a year after Hikma Pharmaceuticals accused Amarin of “deliberately and meticulously” hamstringing supplies of the main ingredient in its only marketed drug, Vascepa, to thwart potential generic competition, Teva Pharmaceuticals has levied a similar challenge.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Arvinas gets grant for treatment of prostate cancer with specific compounds
Pharmaceutical Technology
MARCH 29, 2024
Discover how Arvinas Inc's newly granted patent for compounds treating prostate cancer could revolutionize healthcare. Learn more about the potential for new drugs and therapies.
New tentative approval for MYLAN drug efavirenz, emtricitabine and tenofovir alafenamide
Drug Patent Watch
MARCH 29, 2024
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.
FDA extends review period for Applied Therapeutics’ govorestat NDA
Pharmaceutical Technology
MARCH 29, 2024
The US FDA has extended the review period for Applied Therapeutics' NDA for govorestat to treat classic galactosemia.
GAO Report on Clinical Research Inspections Encourages FDA to Care for its Clinical Inspection Program
FDA Law Blog
MARCH 29, 2024
By John W.M. Claud & Kalie E. Richardson — While Covid is in the rear view for most of us, FDA has had a tough time shaking off the effects of the pandemic on its inspection output. Inspections went down—way down—during the pandemic. In March 2020 , FDA temporarily postponed all foreign and domestic and routine surveillance facility inspections.
China NMPA accepts Astellas’ sBLA for urothelial cancer treatment
Pharmaceutical Technology
MARCH 29, 2024
The CDE of the China NMPA has accepted Astellas Pharma’s sBLA for enfortumab vedotin plus KEYTRUDA to treat urothelial cancer.
Which pharmaceutical drugs have the most drug patents in Japan?
Drug Patent Watch
MARCH 29, 2024
This chart shows the drugs with the most patents in Japan. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.
EC approves Merck’s KEYTRUDA regimen for NSCLC treatment
Pharmaceutical Technology
MARCH 29, 2024
The EC has approved Merck’s KEYTRUDA regimen for adult patients with resectable non-small cell lung cancer at increased recurrence risk.
New patent expiration for Vifor Pharma drug VELTASSA
Drug Patent Watch
MARCH 29, 2024
Annual Drug Patent Expirations for VELTASSA Veltassa is a drug marketed by Vifor Pharma and is included in one NDA. It is available from one supplier.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Intravacc, Primrose to advance conjugate vaccine development
Pharmaceutical Technology
MARCH 29, 2024
Intravacc and Primrose Bio have announced a strategic collaboration aimed at bolstering the conjugate vaccine development and supply.
New patent for Biogen Idec drug SPINRAZA
Drug Patent Watch
MARCH 29, 2024
Annual Drug Patent Expirations for SPINRAZA Spinraza is a drug marketed by Biogen Idec and is included in one NDA. It is available from one supplier.
PTC Therapeutics gets grant for treatment of huntington’s disease using compound of formula (IBBL)
Pharmaceutical Technology
MARCH 29, 2024
Discover the groundbreaking patent granted to PTC Therapeutics Inc for treating Huntington's disease with innovative compounds and pharmaceutical compositions. Explore the potential of Formula (I) and its various forms for effective treatment.
New patent for Genentech Inc drug XOFLUZA
Drug Patent Watch
MARCH 29, 2024
Annual Drug Patent Expirations for XOFLUZA Xofluza is a drug marketed by Genentech Inc and is included in two NDAs. It is available from one supplier.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Let's personalize your content